CD274 and gastric cancer: In the phase 2 KEYNOTE-59 study, 15.5% of 148 patients with PD-L1 CPS ≥ 1 gastric cancer that had progressed after 2 or more prior lines of therapy had radiographic responses to pembrolizumab with a median DOR of 16.3 months (range 1.6–17.3 months) [37], and it was approved by the FDA for this indication.